Infinity Pharmaceuticals Inc. (INFI) Receives $3.50 Average Price Target from Brokerages

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) have been assigned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $3.50.

A number of analysts recently weighed in on INFI shares. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday, March 28th. ValuEngine raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th.

A number of hedge funds have recently added to or reduced their stakes in the business. Savant Capital LLC grew its stake in Infinity Pharmaceuticals by 66.7% in the 4th quarter. Savant Capital LLC now owns 25,000 shares of the biotechnology company’s stock worth $29,000 after buying an additional 10,000 shares in the last quarter. Community Bank N.A. grew its stake in Infinity Pharmaceuticals by 71.4% in the 1st quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock worth $45,000 after buying an additional 10,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Infinity Pharmaceuticals by 54.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock worth $85,000 after buying an additional 15,908 shares in the last quarter. Fosun International Ltd grew its stake in Infinity Pharmaceuticals by 5.4% in the 4th quarter. Fosun International Ltd now owns 378,296 shares of the biotechnology company’s stock worth $424,000 after buying an additional 19,437 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in Infinity Pharmaceuticals by 29.4% in the 4th quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock worth $108,000 after buying an additional 20,721 shares in the last quarter. 54.08% of the stock is owned by institutional investors and hedge funds.

Infinity Pharmaceuticals stock traded up $0.03 during midday trading on Thursday, reaching $1.48. 27,600 shares of the stock were exchanged, compared to its average volume of 190,160. The firm has a market capitalization of $83.68 million, a PE ratio of -7.40 and a beta of 2.10. Infinity Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.19). The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million. As a group, research analysts anticipate that Infinity Pharmaceuticals will post -0.73 earnings per share for the current year.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

See Also: Understanding Market Liquidity

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.